Ubiquitin Protein Ligase UBE3A, which is located on chromosome 15q11–13, is neuron-specifically imprinted and is crucial for brain development and synaptic function. Disruptions in UBE3A gene expression are linked with multiple crucial neurodevelopmental complications, such as Angelman syndrome (AS), Autism spectrum disorder (ASD), and 15q11.2–13.3 duplication syndrome (Dup15q). In the last two decades, there has been extensive in vitro and in vivo modeling of UBE3A that has shed light on its biological functions and the role it plays in these disorders. In comparison, there has been limited in silico analysis of UBE3A. This review therefore highlights recent in silico analyses of UBE3A's molecular interactions, its structure features, and its functional network, providing new insight into its role in neurodevelopmental disorders. The review further discusses new approaches revealed through the application of computational biology for the treatment of UBE3A-related disorders, most importantly of Angelman syndrome.
ZEB2 is a pivotal transcriptional controller which lies at the interface between developmental biology and cancer molecular signatures. In addition to its classical role in the epithelial-mesenchymal transition (EMT), ZEB2 controls immune modulation, stemness, angiogenesis, and therapeutic resistance, thus making it the center of tumor progression and clinical outcome. This review is a unique combination of experimental and in silico data to offer a systems-level of understanding of the regulation of ZEB2 by microRNAs, long non-coding RNAs, chromatin remodeling complexes and transcription factor networks. We also integrate bioinformatics-guided inferences between multi-omics data, to obtain new regulatory substructures, prognostic signatures and drug-response associations. With the mapping of the impact of ZEB2 along developmental pathways, metastatic cascades, and the tumor immune microenvironment, we deduce therapeutic exploitable vulnerabilities and biomarker prospects that have been poorly investigated. The synthesis identifies ZEB2 not only as an actor, but as a key modulator of disease phenotypes, a strong translational target for precision medicine and a blueprint towards computational-experimental research synergy.